Spyre Therapeutics

SYRE

Market cap $909M

Overview Fund Activity

15.05 USD

+0.23

1.55%

At close Updated Sep 17, 4:00 PM EDT

Pre-market

After hours

15.05

0.00

0%

1 day

1.55%

5 days

-7.33%

1 month

-11.16%

3 months

-0.86%

6 months

-18.82%

Year to date

-36.9%

1 year

-47.21%

5 years

-92.25%

10 years

-93.84%

About: Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Employees: 65

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

142% more repeat investments, than reductions

Existing positions increased: 63 | Existing positions reduced: 26

74% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $603K

50% more funds holding in top 10

Funds holding in top 10: 2 [Q1] → 3 (+1) [Q2]

2.49% more ownership

Funds ownership: 103.07% [Q1] → 105.56% (+2.49%) [Q2]

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding

Funds holding: 129 [Q1] → 129 (+0) [Q2]

5% less capital invested

Capital invested by funds: $1B [Q1] → $953M (-$51.7M) [Q2]

See Fund Rankings

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target

$70

365% upside

Avg. target

$70

365% upside

High target

$70

365% upside

1 analyst rating

1 positive

100%

0 neutral

0%

0 negative

0%

BTIG

Julian Harrison

$70

Buy

Reiterated

16 Sep 2025

See Analyst Rankings

Financial journalist opinion

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced that management will participate in a fireside chat and investor meetings at the Stifel 2025 Virtual Immunology and Inflammation Forum. Fireside details below:

Spyre Therapeutics to Participate in Stifel 2025 Virtual Immunology and Inflammation Forum

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 31,900 shares of common stock of Spyre to two non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on September 2, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics Announces Grants of Inducement Awards

The Motley Fool

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

Spyre (SYRE) Q2 R&D Up 23% Loss Narrows

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Reported positive interim Phase 1 results for two next-generation TL1A antibodies, demonstrating both were well-tolerated, exhibited pharmacokinetic ("PK") profiles supporting quarterly or biannual dosing, and full TL1A engagement through up to 20 weeks of follow-up

Spyre Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 60,400 shares of common stock of Spyre to five non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on August 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 121,600 shares of common stock of Spyre to four non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the “2018 Plan”). The stock options were approved on July 1, 2025 and were material to each employee's acceptance of employment with Spyre, in accordance with Nasdaq Listing Rule 5635(c)(4).

Spyre Therapeutics Announces Grants of Inducement Awards

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Spyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerative colitis, while SPY072 will address multiple rheumatological conditions, with large market opportunities and key data readouts expected in 2025-2026. The extended half-life of these candidates could enable infrequent dosing, potentially offering a best-in-class advantage over competitors in the autoimmune and inflammatory disorders space.

Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways Forward

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

SPY002 and SPY072 were well tolerated, exhibited PK that supports quarterly or less frequent dosing, and fully engaged TL1A through up to 20 weeks of follow-up; ~75 day half-life demonstrated, more than 3-fold greater than first-generation anti-TL1A antibodies SKYLINE-UC platform study evaluating three optimized monotherapies and three potentially paradigm-changing combinations in ulcerative colitis, initiated in May 2025 SKYWAY-RD basket study evaluating SPY072 in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) announced, with initiation expected in Q3 2025 Management to host a webcast and conference call today at 8:00 a.m. ET WALTHAM, Mass.

Spyre Therapeutics Announces Positive Interim Phase 1 Results for Two Next-Generation TL1A Antibody Programs, and Provides Clinical Development Updates Expected to Deliver 9 Phase 2 Readouts

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

WALTHAM, Mass. , June 16, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced it will report interim results from the Phase 1 SPY002 healthy volunteer trials on Tuesday, June 17, 2025.

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Spyre Therapeutics Announces Grants of Inducement Awards

WALTHAM, Mass. , June 6, 2025 /PRNewswire/ -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 50,200 shares of common stock of Spyre to three non-executive employees as equity inducement awards under the Spyre Therapeutics, Inc. 2018 Equity Inducement Plan, as amended (the "2018 Plan").

Spyre Therapeutics Announces Grants of Inducement Awards

See News Rankings

Charts implemented using Lightweight Charts™